Diagnostic Criteria and Clinical Implications for Barrett's Esophagus

Introduction to Barrett's Esophagus

The American Gastroenterological Association recommends that Barrett's esophagus be defined as a metaplastic change where columnar epithelium replaces the normal squamous epithelium of the esophagus, requiring the presence of intestinal metaplasia with goblet cells on biopsy 1

The diagnosis of Barrett's esophagus requires both endoscopic and histopathological confirmation, with at least 1 cm of metaplastic columnar epithelium visible in the esophagus and biopsy specimens demonstrating intestinal metaplasia with goblet cells for a definitive diagnosis in the United States 1
The British Society of Gastroenterology historically recognized Barrett's esophagus with gastric metaplasia only, but recent evidence shows that patients with intestinal metaplasia have higher cancer risk than those with gastric-type epithelium alone 1

Approximately 10% of patients with chronic GERD symptoms have Barrett's esophagus, but most GERD patients never develop Barrett's esophagus, even with decades of symptoms 2, 5
The absolute cancer risk remains very low despite the association between GERD and adenocarcinoma, with an annual cancer incidence of approximately 0.00039-0.00065 cases per patient 3, 6
Routine endoscopic screening is not recommended for all GERD patients, as insufficient evidence exists to show that screening decreases cancer incidence or increases life expectancy 3, 4
Barrett's esophagus is the only known precursor to esophageal adenocarcinoma, but progression occurs through dysplasia (low-grade, then high-grade), not through a "pre-Barrett's" stage 1
The cancer risk in GERD without Barrett's is extremely low, making the concept of a "pre-Barrett's" state clinically meaningless 3, 4